Olanzapine Teva 15 mg orodispersible tablets EFG
Spain
Table of Contents
Package leaflet: Information for the user
Introduction
Package leaflet: information for the user
Olanzapina Teva 5 mg orodispersible tablets EFG
Olanzapina Teva 10 mg orodispersible tablets EFG
Olanzapina Teva 15 mg orodispersible tablets EFG
Olanzapina Teva 20 mg orodispersible tablets EFG
olanzapine
Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.
- Keep this leaflet as you may need to read it again.
- If you have any questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only, and you should not give it to other people, even if they have the same symptoms as you, because it may harm them.
- If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.
Leaflet contents
- What Olanzapina Teva is and what it is used for
- What you need to know before taking Olanzapina Teva
- How to take Olanzapina Teva
- Possible side effects
- How to store Olanzapina Teva
- Contents of the pack and other information
1. What Olanzapine Teva is and what it is used for
Olanzapine Teva contains the active substance olanzapine. Olanzapine Teva belongs to a group of medicines called antipsychotics and is indicated for the treatment of the following conditions.
- Schizophrenia, a disorder whose symptoms include hearing, seeing, or sensing things that are not real, false beliefs, unusual suspiciousness, and social withdrawal. People with this condition may also experience depression, anxiety, or tension.
- Moderate to severe manic episodes, characterized by symptoms such as excitement or euphoria.
Olanzapine Teva has been shown to prevent the recurrence of these symptoms in patients with bipolar disorder whose manic episodes have responded to treatment with olanzapine.
2. What you need to know before taking Olanzapine Teva
Do not take Olanzapine Teva
-
if you are allergic to olanzapine or to any of the other ingredients of this medicine (listed in section 6). The allergic reaction may appear as rash, itching, swelling of the face or lips, or difficulty breathing. If this happens to you, tell your doctor.
-
if you have previously been diagnosed with eye problems such as certain types of glaucoma (increased pressure in the eye).
Warnings and precautions
Talk to your doctor or pharmacist before starting to take Olanzapine Teva.
- The use of Olanzapine Teva is not recommended in elderly patients with dementia, as it may cause serious adverse effects.
- Medicines of this type may cause unusual movements, especially in the face or tongue. If this happens after taking Olanzapine Teva, tell your doctor.
- Very rarely, medicines of this type may cause a combination of fever, rapid breathing, sweating, muscle stiffness, and mental confusion or drowsiness. If this occurs, contact your doctor immediately.
- Weight gain has been observed in patients taking Olanzapine Teva. You and your doctor should monitor your weight regularly. If necessary, your doctor may help you plan a diet or consider referring you to a dietitian.
- Increased levels of blood sugar and fats (triglycerides and cholesterol) have been observed in patients taking Olanzapine Teva. Your doctor should perform blood tests to monitor your blood sugar and fat levels before you start taking Olanzapine Teva and regularly during treatment.
- If you or someone in your family has a history of blood clots, consult your doctor, as medicines of this type have been associated with blood clot formation.
If you have any of the following conditions, inform your doctor as soon as possible:
- Stroke or “mini” stroke (transient ischemic attack – temporary stroke symptoms).
- Parkinson’s disease
- Prostate problems
- Intestinal blockage (paralytic ileus)
- Liver or kidney disease
- Blood disorders
- Heart disease
- Diabetes
- Seizures
- If you think you may have lost body salts due to prolonged severe diarrhea or vomiting, or from using diuretic medicines (water tablets)
If you have dementia, you or your caregiver or family member should inform your doctor if you have ever had a stroke or reduced blood flow to the brain.
As a routine precaution, if you are over 65 years old, your doctor should monitor your blood pressure.
Children and adolescents
Patients under 18 years of age must not take Olanzapine Teva.
Other medicines and Olanzapine Teva
Tell your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.
Only use other medicines together with Olanzapine Teva if your doctor has approved it. You may feel drowsy if you combine Olanzapine Teva with antidepressants or medicines for anxiety or sleep (tranquilizers).
Specifically, tell your doctor if you are taking:
- Medication for Parkinson’s disease
- Carbamazepine (an antiepileptic and mood stabilizer), fluvoxamine (an antidepressant), or ciprofloxacin (an antibiotic). Your dose of Olanzapine Teva may need to be adjusted.
Use of Olanzapine Teva with alcohol
Do not drink alcohol while taking Olanzapine Teva, as it may increase drowsiness.
Pregnancy and breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor before using this medicine.
You must not take this medicine while breastfeeding, as small amounts of Olanzapine Teva may pass into breast milk.
The following symptoms may occur in newborns whose mothers have used Olanzapine Teva during the third trimester (last three months of pregnancy): tremors, muscle stiffness and/or weakness, drowsiness, agitation, breathing difficulties, and feeding problems. If your baby shows any of these symptoms, contact your doctor.
Driving and using machines
There is a risk of drowsiness when taking Olanzapine Teva. If this occurs, do not drive or operate machinery. Discuss this with your doctor.
Olanzapine Teva contains lactose, sucrose, and aspartame
This medicine contains lactose and sucrose. If your doctor has informed you that you have an intolerance to certain sugars, consult with them before taking this medicine.
This medicine contains 2.25 mg/4.5 mg/6.75 mg/9 mg of aspartame in each 5 mg/10 mg/15 mg/20 mg orodispersible tablet. Aspartame is a source of phenylalanine, which may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body cannot eliminate it properly.
3. How to take Olanzapina Teva
Follow exactly the dosing instructions for this medicine provided by your doctor. If you are unsure, consult your doctor or pharmacist again.
Your doctor will tell you how many Olanzapina Teva tablets you should take and for how long. The daily dose of Olanzapina Teva ranges between 5 mg and 20 mg. Consult your doctor if your symptoms return, but do not stop taking Olanzapina Teva unless your doctor tells you to.
Olanzapina Teva tablets should be taken once daily, as directed by your doctor. Try to take the tablets at the same time each day. You may take them with or without food. Olanzapina Teva orodispersible tablets are for oral administration.
Olanzapina Teva tablets are easily crumbled and therefore must be handled with care. Do not handle the tablets with wet hands, as they may disintegrate. Place your tablet in the mouth. It will dissolve directly in the mouth and can then be chewed easily.
Alternatively, the tablet may be placed into a glass or cup filled with water, orange juice, apple juice, milk, or coffee, and stirred. With some drinks, the mixture may change color and appear cloudy. The mixture should be drunk immediately.
If you take more Olanzapina Teva than you should
Patients who have taken more Olanzapina than prescribed have experienced the following symptoms: rapid heartbeat, agitation/aggression, speech problems, unusual movements (especially of the face and tongue), and reduced level of consciousness. Other possible symptoms include: acute confusion, seizures (epilepsy), coma, a combination of fever, rapid breathing, sweating, muscle rigidity, drowsiness or lethargy, slowed breathing rate, aspiration, increased blood pressure or decreased blood pressure, and abnormal heart rhythms. Contact your doctor immediately or go to the hospital if you experience any of the symptoms listed above. Show the doctor the package with the tablets.
If you forget to take Olanzapina Teva
Take your tablet as soon as you remember. Do not take a double dose to make up for forgotten doses.
If you stop taking Olanzapina Teva
Do not stop treatment just because you feel better. It is very important that you continue taking Olanzapina Teva for as long as your doctor instructs.
If you stop taking Olanzapina Teva suddenly, symptoms such as sweating, inability to sleep, tremor, anxiety, or nausea and vomiting may occur. Your doctor may advise you to gradually reduce the dose before stopping treatment.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
4. Possible adverse effects
Like all medicines, this medicine can cause adverse effects, although not everybody gets them.
Contact your doctor immediately if you experience:
- unusual movements (a common adverse effect which may affect up to 1 in 10 people), especially of the face or tongue.
- blood clots in the veins (an uncommon adverse effect which may affect up to 1 in 100 people), especially in the legs (symptoms include sweating, pain and redness in the leg), which may travel through the bloodstream to the lungs,
- causing chest pain and difficulty breathing. If you experience any of these symptoms, seek medical attention immediately.
- a combination of fever, rapid breathing, sweating, muscle stiffness, and mental confusion or drowsiness (frequency cannot be estimated from available data).
Very common adverse effects (may affect more than 1 in 10 people) include weight gain, drowsiness, and increased levels of prolactin in the blood. In the early stages of treatment, some people may feel dizzy or faint (with slower heartbeats), especially when getting up from lying down or sitting. This sensation usually resolves spontaneously, but if it does not, consult your doctor.
Common adverse effects (may affect up to 1 in 10 people) include changes in levels of certain blood cells and circulating lipids, and temporary increases at the beginning of treatment in liver enzymes; increased levels of blood and urine sugar; increased levels of uric acid and creatine phosphokinase in the blood; increased appetite; dizziness; restlessness; tremor; unusual movements (dyskinesia); constipation; dry mouth; skin rash; loss of strength; excessive tiredness; fluid retention causing swelling of the hands, ankles or feet; fever; joint pain; and sexual dysfunction such as decreased libido in men and women or erectile dysfunction in men.
Uncommon adverse effects (may affect up to 1 in 100 people) include hypersensitivity (e.g. swelling of the mouth and throat, itching, skin rash), diabetes or worsening of diabetes, occasionally associated with ketoacidosis (ketones in blood and urine) or coma; seizures, mostly in patients with a history of seizures (epilepsy); muscle stiffness or spasms (including eye movements); restless legs syndrome; speech problems, stuttering; slow pulse; sensitivity to sunlight; nosebleeds; abdominal distension; excessive salivation; memory loss or forgetfulness; urinary incontinence; loss of ability to urinate; hair loss; absence or reduction of menstrual periods; and changes in the breast gland in both men and women such as abnormal production of breast milk or abnormal growth.
Rare adverse effects (may affect up to 1 in 1,000 people) include decreased body temperature; abnormal heart rhythm; sudden unexplained death; blood clots such as deep vein thrombosis in the legs and blood clots in the lung; inflammation of the pancreas causing severe stomach pain, fever and malaise; liver disease, with yellowing of the skin and whites of the eyes; muscle disorder presenting as unexplained muscle pain; and prolonged and/or painful erection.
Serious allergic reactions have been reported, such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). DRESS initially presents with flu-like symptoms, a skin rash starting on the face and spreading to other areas, fever, swollen lymph nodes, elevated liver enzymes in blood tests, and an increase in a type of white blood cell (eosinophilia).
During treatment with olanzapine, elderly patients with dementia may experience stroke, pneumonia, urinary incontinence, falls, extreme fatigue, visual hallucinations, increased body temperature, skin redness, and difficulty walking. Some deaths have been reported in this particular group of patients.
Olanzapina Teva may worsen symptoms in patients with Parkinson's disease.
Reporting of adverse effects
If you experience any type of adverse effect, talk to your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly through the national reporting system listed in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.
5. Storage of Olanzapine Teva
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the cardboard carton following "EXP". The expiry date refers to the last day of the month indicated.
Store in the original packaging to protect from light.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of any unused packaging and medicines. This will help protect the environment.
6. Contents of the pack and other information
Composition of Olanzapine Teva
- The active substance is olanzapine.
Each orodispersible tablet of Olanzapine Teva 5 mg contains 5 mg of active substance.
Each orodispersible tablet of Olanzapine Teva 10 mg contains 10 mg of active substance.
Each orodispersible tablet of Olanzapine Teva 15 mg contains 15 mg of active substance.
Each orodispersible tablet of Olanzapine Teva 20 mg contains 20 mg of active substance.
- The other components are mannitol, aspartame (E951), magnesium stearate, crospovidone type B, lactose monohydrate, hydroxypropylcellulose, and lemon flavour [flavouring preparation(s), maltodextrin, sucrose, arabic gum (E414), glyceryl triacetate (E1518) and alpha-tocopherol (E307)].
Nature and contents of the container
Orodispersible tablets are the technical name for tablets that dissolve directly in the mouth, making them easier to swallow.
Olanzapine Teva 5 mg orodispersible tablets are yellow, round, biconvex, 8 mm in diameter.
Olanzapine Teva 10 mg orodispersible tablets are yellow, round, biconvex, 10 mm in diameter.
Olanzapine Teva 15 mg orodispersible tablets are yellow, round, biconvex, 11 mm in diameter.
Olanzapine Teva 20 mg orodispersible tablets are yellow, round, biconvex, 12 mm in diameter.
Carton packs of Olanzapine Teva 5 mg, 10 mg and 15 mg orodispersible tablets contain 28, 30, 35, 50, 56, 70 or 98 tablets.
Packs of Olanzapine Teva 20 mg orodispersible tablets contain 28, 30, 35, 56, 70 or 98 tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder
Teva B.V.
Swensweg 5
2031GA Haarlem
The Netherlands
Manufacturer
Teva Pharmaceutical Works Co. Ltd
Pallagi út 13
4042 Debrecen
Hungary
TEVA PHARMA S.L.U.
Poligono Industrial Malpica, c/C, no. 4
50.016 Zaragoza
Spain
Merckle GmbH
Ludwig-Merckle-Strasse 3
89143 Blaubeuren
Germany
Teva Pharma B.V.
Swensweg 5
2031 GA Haarlem
The Netherlands
For more information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:
Belgium/Belgium/Belgium Teva Pharma Belgium N.V./S.A./AG Tel/Tel: +32 38207373 | Lithuania UAB Teva Baltics Tel: +370 52660203 |
| Luxembourg/Luxembourg Teva Pharma Belgium N.V./S.A./AG Belgium/Belgium Tel/Tel: +32 38207373 |
Czech Republic Teva Pharmaceuticals CR, s.r.o. Tel: +420 251007111 | Hungary Teva Gyógyszergyár Zrt. Tel: +36 12886400 |
Denmark SanoSwiss UAB Lithuania Tlf: +370 70001320 | Malta Teva Pharmaceuticals Ireland Ireland Tel: +44 2075407117 |
Germany TEVA GmbH Tel: +49 73140208 | Netherlands Teva Nederland B.V. Tel: +31 8000228400 |
Estonia UAB Teva Baltics Estonian branch Tel: +372 6610801 | Norway Teva Norway AS Tlf: +47 66775590 |
Greece Specifar A.B.E.E. Tel: +30 2118805000 | Austria ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1970070 |
Spain Teva Pharma, S.L.U. Tel: +34 913873280 | Poland Teva Pharmaceuticals Polska Sp. z o.o. Tel: +48 223459300 |
France Teva Santé Tél: +33 155917800 | Portugal Teva Pharma - Produtos Farmacêuticos, Lda. Tel: +351 214767550 |
Croatia Pliva Hrvatska d.o.o. Tel: +385 13720000 | Romania Teva Pharmaceuticals S.R.L. Tel: +40 212306524 |
Ireland Teva Pharmaceuticals Ireland Tel: +44 2075407117 | Slovenia Pliva Ljubljana d.o.o. Tel: +386 15890390 |
Iceland Teva Pharma Iceland ehf. Sími: +354 5503300 | Slovakia TEVA Pharmaceuticals Slovakia s.r.o. Tel: +421 257267911 |
Italy Teva Italia S.r.l. Tel: +39 028917981 | Finland Teva Finland Oy Puh/Tel: +358 201805900 |
Cyprus Specifar A.B.E.E. Greece Tel: +30 2118805000 | Sweden Teva Sweden AB Tel: +46 42121100 |
Latvia UAB Teva Baltics branch Latvia Tel: +371 67323666 | United Kingdom (Northern Ireland) Teva Pharmaceuticals Ireland Ireland Tel: +44 2075407117 |
Date of the most recent review of this leaflet: <{MM/YYYY}><{month YYYY}>.
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu/.
